FDA wants to regulate lab-developed tests.
The FDA’s Proposed Rule to Regulate Lab-Developed Tests Sparks Controversy
The U.S. Food and Drug Administration (FDA) has recently proposed a rule that would bring laboratory-developed tests (LDTs) under its regulatory authority. This decision has sparked controversy, especially considering the Trump administration’s opposition to FDA regulation of COVID-19 tests during the pandemic.
LDTs are testing services developed by clinical labs and hospitals, designed and used within a single laboratory for clinical purposes. Unlike commercially manufactured tests, LDTs are created to fulfill unmet clinical needs or when commercial tests are unavailable.
According to the Association for Molecular Pathology, these tests play a crucial role in early diagnosis and monitoring of patient treatment.Related Stories
These tests are used to measure or detect substances in the body, such as glucose, proteins, cholesterol, or DNA, according to the FDA.
Previously, LDTs were not required to have FDA approval for marketing, unlike commercially developed tests. However, the proposed rule aims to change that.Safety Concerns
The FDA’s rule is aimed at ensuring the safety and effectiveness of these tests, which are increasingly used in healthcare decisions. The agency has raised concerns about the accuracy and performance of some LDTs compared to FDA-authorized tests.
The FDA is worried that inaccurate test results could lead to unnecessary or delayed treatment, potentially causing harm to patients. Interestingly, the Trump administration had opposed FDA regulation of lab-developed tests, but this requirement was lifted in 2020.
According to The New York Times, this deregulatory action aimed to better prepare for future pandemics while maintaining quality and accuracy. However, during the early stages of the COVID-19 outbreak, lab-developed tests became crucial after faulty tests from the U.S. Centers for Disease Control and Prevention caused delays in widespread testing.FDA’s New Rules
The FDA’s proposed rule acknowledges that lab-developed tests have evolved and are now used more widely, impacting a larger and more diverse population.
The FDA Commissioner, Dr. Robert M. Califf, emphasized the importance of accurate and valid test results, as they significantly influence medical decisions. The agency cited instances where lab-developed tests led to inappropriate therapies, improper treatment, and incorrect diagnoses.
While testing laboratories are regulated by the Centers for Medicare and Medicaid Services, they do not evaluate test accuracy or require adverse event reporting, as reported by Axios.The proposed rule would classify lab-developed tests as in vitro diagnostic products (IVDs) and bring them under the Federal Food, Drug, and Cosmetic Act. This would allow the FDA to treat these tests like medical devices and enhance its oversight.
According to Axios, the FDA plans to phase in regulation over five years, aiming to reduce healthcare costs associated with ineffective or unsafe tests.FDA Overstepping Authority
The Center for Science in the Public Interest (CSPI) supports the FDA’s proposed rule, stating that oversight of lab-developed tests would ensure reliable results. The CSPI commends the FDA for including tests for rare diseases in the regulation to protect patients from inaccurate results.
However, the American Clinical Laboratory Association (ACLA) opposes the FDA’s decision, arguing that the FDA lacks the statutory authority to regulate lab-developed tests as medical devices. The ACLA believes that any expansion of the FDA’s role should be tailored by Congress to fit the unique characteristics of lab-developed tests.
In the past, the FDA faced industry opposition when attempting to regulate lab-developed tests. Although lawmakers started working on legislation in 2018, progress has been slow.
What are the main concerns raised by opponents of the FDA’s proposed rule to regulate LDTs?
New rule would make it mandatory for all LDTs to undergo FDA review and obtain marketing authorization before they can be used clinically. The rule would require labs to submit their LDTs to the FDA for evaluation, including evidence of analytical and clinical validity, as well as data on test performance and reliability.
Opponents of the proposed rule argue that it would stifle innovation and hinder the ability of labs to quickly develop and deploy tests in response to emerging health threats. They argue that the FDA’s review process is time-consuming and costly, which could delay the availability of important tests during public health emergencies.
Proponents of the rule, on the other hand, believe that FDA oversight is necessary to ensure the quality and accuracy of LDTs. They argue that some labs have been offering tests without sufficient evidence of their performance, leading to false results and potentially endangering patient safety.
The COVID-19 pandemic has highlighted the importance of accurate and reliable testing, and the role that LDTs can play in addressing public health crises. The FDA’s proposed rule comes at a time when the country is grappling with the challenges of widespread testing and the need for timely and accurate results.
The controversy surrounding the FDA’s proposed rule reflects a broader debate about the appropriate level of regulatory oversight for LDTs. While regulation can provide assurance of test accuracy and reliability, it must also strike a balance with the need for innovation and timely access to tests.
The FDA is seeking public input on the proposed rule, and stakeholders from various sectors, including laboratories, healthcare providers, patient advocacy groups, and industry associations, have been actively engaged in the debate. It remains to be seen how the FDA will address the concerns raised by opponents and whether any modifications will be made to the rule in response to public feedback.
In conclusion, the FDA’s proposed rule to regulate LDTs has sparked controversy regarding the appropriate level of regulatory oversight for these tests. While the FDA aims to ensure the safety and effectiveness of LDTs, opponents argue that the rule could stifle innovation and hinder the rapid development of tests during public health emergencies. The debate surrounding this issue highlights the need to strike a balance between regulation and innovation in order to best serve the interests of patients and public health.
" Conservative News Daily does not always share or support the views and opinions expressed here; they are just those of the writer."
*As an Amazon Associate I earn from qualifying purchases
Now loading...